Idexx Laboratories, Inc. (IDXX) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Idexx Laboratories financial statements at a glance

Idexx Laboratories reported revenue of $4.30 billion for fiscal year 2025 (ended December 31, 2025), up 10.4% from fiscal year 2024. Net income was $1.06 billion, a net margin of 24.6%, and diluted earnings per share were $13.08.

At the end of fiscal year 2025 it had total assets of $3.35 billion, total liabilities of $1.75 billion and shareholders' equity of $1.61 billion, with cash and short-term investments of $180.07 million and total debt of $976.06 million.

Its operations brought in $1.18 billion of cash; capital spending was $138.23 million, leaving free cash flow of $1.04 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

IDXX logo

Idexx Laboratories, Inc.

IDXXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
4.30B
Prev Year: 3.90B
YoY: +10.4%
Operating Revenue
4.30B
Prev Year: 3.90B
YoY: +10.4%
Normalized EBITDA
1.51B
Prev Year: 1.27B
YoY: +18.7%
Tax Rate for Calcs
0.2
Prev Year: 0
Selling and Marketing Expense
643.55M
Prev Year: 588.51M
YoY: +9.4%
General and Administrative Expense
404.79M
Prev Year: 442.29M
YoY: -8.5%
Other General and Administrative
404.79M
Prev Year: 442.29M
YoY: -8.5%
Cost of Revenue
1.64B
Prev Year: 1.52B
YoY: +8.3%
Gross Profit
2.66B
Prev Year: 2.38B
YoY: +11.8%
Operating Expense
1.30B
Prev Year: 1.25B
YoY: +3.9%
Selling General and Administrative
1.05B
Prev Year: 1.03B
YoY: +1.7%
Research and Development
251.21M
Prev Year: 219.79M
YoY: +14.3%
Operating Income
1.36B
Prev Year: 1.13B
YoY: +20.5%
Net Non Operating Interest Income Expense
-35.84M
Prev Year: -18.51M
YoY: -93.7%
Non-operating Interest Income
3.01M
Prev Year: 12.70M
YoY: -76.3%
Non-operating Interest Expense
38.85M
Prev Year: 31.20M
YoY: +24.5%
Pre-tax Income
1.32B
Prev Year: 1.11B
YoY: +19.3%
Provision for Income Taxes
264.73M
Prev Year: 221.96M
YoY: +19.3%
Net Income Common Stockholders
1.06B
Prev Year: 887.87M
YoY: +19.3%
Net Income
1.06B
Prev Year: 887.87M
YoY: +19.3%
Net Income Including Non-Controlling Interests
1.06B
Prev Year: 887.87M
YoY: +19.3%
Net Income from Continuing Operations
1.06B
Prev Year: 887.87M
YoY: +19.3%
Diluted NI Available to Com Stockholders
1.06B
Prev Year: 887.87M
YoY: +19.3%
Basic EPS
13.17
Prev Year: 10.77
YoY: +22.3%
Diluted EPS
13.08
Prev Year: 10.67
YoY: +22.6%
Weighted Average Shares (basic)
80.43M
Prev Year: 82.47M
YoY: -2.5%
Weighted Average Shares (diluted)
81.03M
Prev Year: 83.25M
YoY: -2.7%
Total Operating Income as Reported
1.36B
Prev Year: 1.13B
YoY: +20.5%
Total Expenses
2.94B
Prev Year: 2.77B
YoY: +6.3%
Net Income from Continuing and Discontinued Operation
1.06B
Prev Year: 887.87M
YoY: +19.3%
Normalized Income
1.06B
Prev Year: 887.87M
YoY: +19.3%
Interest Income
3.01M
Prev Year: 12.70M
YoY: -76.3%
Interest Expense
38.85M
Prev Year: 31.20M
YoY: +24.5%
Net Interest Income
-35.84M
Prev Year: -18.51M
YoY: -93.7%
EBIT
1.36B
Prev Year: 1.14B
YoY: +19.5%
EBITDA
1.51B
Prev Year: 1.27B
YoY: +18.7%
Reconciled Cost of Revenue
1.64B
Prev Year: 1.52B
YoY: +8.3%
Reconciled Depreciation
145.18M
Prev Year: 129.94M
YoY: +11.7%
Net Income from Continuing Operation Net Minority Interest
1.06B
Prev Year: 887.87M
YoY: +19.3%
Values in USD

Idexx Laboratories key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$4.3B$3.9B$3.7B$3.4B$3.2B
Gross profit$2.7B$2.4B$2.2B$2.0B$1.9B
Operating income$1.4B$1.1B$1.1B$898.8M$932.0M
Net income$1.1B$887.9M$845.0M$679.1M$744.8M
Diluted EPS$13.08$10.67$10.06$8.03$8.60
Total assets$3.4B$3.3B$3.3B$2.7B$2.4B
Total liabilities$1.7B$1.7B$1.8B$2.1B$1.7B
Shareholders' equity$1.6B$1.6B$1.5B$608.7M$690.0M
Cash and short-term investments$180.1M$288.3M$453.9M$112.5M$144.5M
Total debt$976.1M$986.9M$1.1B$1.5B$1.0B
Operating cash flow$1.2B$929.0M$906.5M$543.0M$755.5M
Capital spending$138.2M$130.9M$133.6M$158.8M$119.5M
Free cash flow$1.0B$798.1M$772.9M$384.1M$636.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Idexx Laboratories's revenue in fiscal year 2025?

$4.30 billion, up 10.4% from $3.90 billion in fiscal year 2024.

How much profit does Idexx Laboratories make?

Idexx Laboratories reported net income of $1.06 billion for fiscal year 2025 (24.6% of revenue); operating income was $1.36 billion.

How much cash and debt does Idexx Laboratories have?

At the end of fiscal year 2025: cash and short-term investments of $180.07 million and total debt of $976.06 million.

What is Idexx Laboratories's free cash flow?

$1.04 billion in fiscal year 2025 (operating cash flow of $1.18 billion minus capital spending of $138.23 million).

MoreIdexx Laboratories stock overviewIdexx Laboratories executive teamIdexx Laboratories shareholdersIdexx Laboratories revenue by segment
RelatedIn-Vitro Diagnostic Substance Manufacturing industryManufacturing sectorZoetis financialsElanco Animal Health financialsPhibro Animal Health (PAHC)ImmuCell (ICCC)Zhengye Biotechnology Holding (ZYBT)Provectus Biopharmaceuticals (PVCT)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube